Axsome Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AXSM and other ETFs, options, and stocks.

About AXSM

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. 

CEO
Herriott Tabuteau
CEOHerriott Tabuteau
Employees
925
Employees925
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2012
Founded2012
Employees
925
Employees925

AXSM Key Statistics

Market cap
12.04B
Market cap12.04B
Price-Earnings ratio
-62.53
Price-Earnings ratio-62.53
Dividend yield
Dividend yield
Average volume
1.58M
Average volume1.58M
High today
$249.00
High today$249.00
Low today
$230.14
Low today$230.14
Open price
$248.34
Open price$248.34
Volume
786.41K
Volume786.41K
52 Week high
$260.19
52 Week high$260.19
52 Week low
$96.09
52 Week low$96.09

Stock Snapshot

As of today, Axsome Therapeutics(AXSM) shares are valued at $233.80. The company's market cap stands at 12.04B, with a P/E ratio of -62.53.

During the trading session on 2026-07-11, Axsome Therapeutics(AXSM) shares reached a daily high of $249.00 and a low of $230.14. At a current price of $233.80, the stock is +1.6% higher than the low and still -6.1% under the high.

Trading activity shows a volume of 786.41K, compared to an average daily volume of 1.58M.

The stock's 52-week range extends from a low of $96.09 to a high of $260.19.

The stock's 52-week range extends from a low of $96.09 to a high of $260.19.

AXSM News

The Motley Fool 2d
Better Growth Buy: Axsome vs Revolution Medicines - The Motley Fool

...

Better Growth Buy: Axsome vs Revolution Medicines - The Motley Fool
Simply Wall St 6d
The Bull Case For Axsome Therapeutics Could Change Following Phase 3 ADHD Trial And Index Moves

Axsome Therapeutics, Inc. recently reported dosing the first patient in its FOCUS-3 Phase 3 trial of solriamfetol for adolescents with ADHD, while also being ad...

The Bull Case For Axsome Therapeutics Could Change Following Phase 3 ADHD Trial And Index Moves

Analyst ratings

90%

of 21 ratings
Buy
90.5%
Hold
9.5%
Sell
0%

People also own

Based on the portfolios of people who own AXSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.